{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:04:42Z","timestamp":1791212682548,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"vor","delay-in-days":1251,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1074\/jbc.m116.772996","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T01:10:19Z","timestamp":1487812219000},"page":"6202-6212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3\/4A protease from genotype 1a"],"prefix":"10.1016","volume":"292","author":[{"given":"Zhuyan","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"McMonagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Ingravallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Chase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Curry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Asante-Appiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1074\/jbc.M116.772996_bib1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","article-title":"The global burden of hepatitis C","volume":"29","author":"Lavanchy","year":"2009","journal-title":"Liver Int"},{"key":"10.1074\/jbc.M116.772996_bib2","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"key":"10.1074\/jbc.M116.772996_bib3","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.24641","article-title":"An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases","volume":"54","author":"Ghany","year":"2011","journal-title":"Hepatology"},{"key":"10.1074\/jbc.M116.772996_bib4","unstructured":"World Health Organization. (2016) Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection updated version. April 2016, WHO Document Production Services, Geneva, Switzerland."},{"key":"10.1074\/jbc.M116.772996_bib5","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1128\/JVI.74.4.2046-2051.2000","article-title":"Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3\u2032-nontranslated region are essential for virus replication in vivo","volume":"74","author":"Kolykhalov","year":"2000","journal-title":"J. Virol"},{"key":"10.1074\/jbc.M116.772996_bib6","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1128\/AAC.50.3.1013-1020.2006","article-title":"SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of \u03b1-interferon in replicon cells","volume":"50","author":"Malcolm","year":"2006","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1074\/jbc.M116.772996_bib7","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1128\/AAC.50.3.899-909.2006","article-title":"Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3\u20134A serine protease","volume":"50","author":"Perni","year":"2006","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1074\/jbc.M116.772996_bib8","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1021\/jm401507s","article-title":"Discovery and development of simeprevir (TMC435), a HCV NS3\/4A protease inhibitor","volume":"57","author":"Rosenquist","year":"2014","journal-title":"J. Med. Chem"},{"key":"10.1074\/jbc.M116.772996_bib9","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1128\/AAC.04227-14","article-title":"In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3\/4A protease inhibitor ABT-450","volume":"59","author":"Pilot-Matias","year":"2015","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1074\/jbc.M116.772996_bib10","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1021\/ja711120r","article-title":"Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3\/4A protease","volume":"130","author":"Liverton","year":"2008","journal-title":"J. Am. Chem. Soc"},{"key":"10.1074\/jbc.M116.772996_bib11","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1021\/ml300017p","article-title":"Discovery of MK-5172, a macrocyclic hepatitis C virus NS3\/4a protease inhibitor","volume":"3","author":"Harper","year":"2012","journal-title":"ACS Med. Chem. Lett"},{"key":"10.1074\/jbc.M116.772996_bib12","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(14)61795-5","volume":"385","author":"Lawitz","year":"2015","journal-title":"Lancet"},{"key":"10.1074\/jbc.M116.772996_bib13","doi-asserted-by":"crossref","first-page":"S677","DOI":"10.1016\/S0168-8278(15)31094-1","volume":"62","author":"Black","year":"2015","journal-title":"J. Hepatol"},{"key":"10.1074\/jbc.M116.772996_bib14","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/hep.27934","article-title":"Hepatitis C virus drug resistance-associated substitutions: state of the art summary","volume":"62","author":"Lontok","year":"2015","journal-title":"Hepatology"},{"key":"10.1074\/jbc.M116.772996_bib15","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","article-title":"Simeprevir with pegylated interferon \u03b1 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"384","author":"Jacobson","year":"2014","journal-title":"Lancet"},{"key":"10.1074\/jbc.M116.772996_bib16","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jhep.2014.11.032","article-title":"Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon\/ribavirin in Phase IIb\/III studies","volume":"62","author":"Lenz","year":"2015","journal-title":"J. Hepatol"},{"key":"10.1074\/jbc.M116.772996_bib17","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1016\/S2352-3018(15)00114-9","article-title":"Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial","volume":"2","author":"Rockstroh","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1074\/jbc.M116.772996_bib18","doi-asserted-by":"crossref","first-page":"e1002832","DOI":"10.1371\/journal.ppat.1002832","article-title":"The molecular basis of drug resistance against hepatitis C virus NS3\/4A protease inhibitors","volume":"8","author":"Romano","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1074\/jbc.M116.772996_bib19","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1128\/AAC.00777-10","article-title":"Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors","volume":"54","author":"Bae","year":"2010","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1074\/jbc.M116.772996_bib20","series-title":"Molecular Cloning: A Laboratory Manual","author":"Green","year":"2012"},{"key":"10.1074\/jbc.M116.772996_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ab.2007.10.041","article-title":"A time-resolved, internally quenched fluorescence assay to characterize inhibition of hepatitis C virus nonstructural protein 3-4A protease at low enzyme concentrations","volume":"373","author":"Mao","year":"2008","journal-title":"Anal. Biochem"},{"key":"10.1074\/jbc.M116.772996_bib22","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1126\/science.290.5498.1972","article-title":"Efficient initiation of HCV RNA replication in cell culture","volume":"290","author":"Blight","year":"2000","journal-title":"Science"},{"key":"10.1074\/jbc.M116.772996_bib23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1126\/science.285.5424.110","article-title":"Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line","volume":"285","author":"Lohmann","year":"1999","journal-title":"Science"},{"key":"10.1074\/jbc.M116.772996_bib24","doi-asserted-by":"crossref","first-page":"7904","DOI":"10.1128\/JVI.78.15.7904-7915.2004","article-title":"Adaptive mutations producing efficient replication of genotype 1a hepatitis C virus RNA in normal Huh7 cells","volume":"78","author":"Yi","year":"2004","journal-title":"J. Virol"},{"key":"10.1074\/jbc.M116.772996_bib25","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.gastro.2010.10.056","article-title":"Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus","volume":"140","author":"Shimakami","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1074\/jbc.M116.772996_bib26","series-title":"AMBER 2016","author":"Case","year":"2016"},{"key":"10.1074\/jbc.M116.772996_bib27","doi-asserted-by":"crossref","first-page":"6474","DOI":"10.1021\/jp003919d","article-title":"Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides","volume":"105","author":"Kaminski","year":"2001","journal-title":"J. Phys. Chem. B"},{"key":"10.1074\/jbc.M116.772996_bib28","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/jcc.10128","article-title":"Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation","volume":"23","author":"Jakalian","year":"2002","journal-title":"J. Comput. Chem"}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925820449567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925820449567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1074\/jbc.M116.772996","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T14:05:35Z","timestamp":1641305135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925820449567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":28,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0021925820449567"],"URL":"https:\/\/doi.org\/10.1074\/jbc.m116.772996","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3\/4A protease from genotype 1a","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1074\/jbc.M116.772996","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}]}}